Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ProBioGen Closes Master Service Agreement with NextPoint | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

ProBioGen Closes Master Service Agreement with NextPoint

Initiates development and GMP manufacturing of NextPoint’s lead antibody candidate.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

ProBioGen has closed a Master Service Agreement with NextPoint and initiated development and GMP manufacturing of their lead antibody candidate.
 
ProBioGen’s CHO.RiGHT cell line development including its latest DirectedLuck transposase and platform processes enable the development to provide a high-expressing stable cell line and a robust manufacturing process. Further, ProBioGen’s proprietary cell culture medium makes manufacturing processes even more robust, with improved protein titers and cell growth behavior. The integrated services ensure that NextPoint can bring its molecule to the clinic in a timely manner.
 
“We are proud NextPoint has selected us for this fast track CMC development and manufacturing of its unique antibody that targets a novel immune checkpoint axis offering promise for hard to treat cancers. We are thrilled to support them with our expertise and technology to move this candidate towards the clinic,” says Dr. Gabriele Schneider, chief business offer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics